Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs.

Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors.

CV ansehen CV ausblenden

Aktuelle News & Insights

Private Equity

Advising Rutland Partners on JSM Group investment

26. Februar 2021

von mehreren Autoren

Klicken Sie hier für Details
Life Sciences & Healthcare

Acting on transformational roll-up and $250 million crossover financing of cutting-edge UK and European biotech companies

16. Februar 2021

von Ross McNaughton und Colin McCall

Klicken Sie hier für Details
Life Sciences & Healthcare

Edison Open House Global Healthcare 2021 – key takeaways from our panel

4. Februar 2021
Quick read

von mehreren Autoren

Klicken Sie hier für Details
pipette
Synapse

Private equity investment in life sciences sector

30. Juli 2020
IN-DEPTH ANALYSIS

von mehreren Autoren

Klicken Sie hier für Details

Meet me at

Alle Veranstaltungen und Webinare finden Sie auf unserer Event-Seite.